Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Clinical trial NCT05049681 · UNKNOWN

Trial details

NCT number: NCT05049681
Sponsor: Feng Wang
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Esophageal Cancer

Start date: 2021-12-05
Primary completion: 2022-12-20
Enrollment: 234

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.